

Half-Year Report 2007

SHL TeleMedicine Ltd.

1 January - 30 June



Dear Shareholders,
SHL Telemedicine's results for Q2 in line with expectations. SHL expects to announce significant transaction regarding its US business in coming days.

Focus on figures

SHL's revenues for the second quarter of 2007 amounted to USD 20.3 million compared to USD 21.0 million in Q2 of 2006 with revenues for the half year totalling USD 40.3 million against revenues of USD 41.5 million in H1 2006. Revenues from Germany continued to display good growth together with those of Israel while in the US, revenues declined mainly due to the divestment of the CVI centres over the past year.

Gross margins remained steady with gross profit amounting to USD 9.7 million and USD 19.2 million in Q2 and H1 of 2007 respectively, compared to USD 10.1 million and USD 20.0 million in Q2 and H1 of 2006.

EBITDA and EBIT for the quarter amounted to USD 2.0 million and USD 0.2 million respectively, compared to USD 3.1 million and USD 1.3 million in Q2 of 2006.

EBITDA and EBIT for the half year amounted to USD 4.2 million and USD 0.6 million compared to USD 6.2 million and USD 2.6 million in the first half of 2006. This decrease in operating results was mainly due to increased provisions and restructuring costs relating to its overall US operations.

After the recording of a further charge of USD 1.0 million relating to the discontinued operations from the US imaging centres, SHL's net income for the first half of 2007 amounted to USD 0.6 million compared with a net loss of USD 3.9 million in the first half of 2006. Net loss for the first half of 2007 attributable to SHL shareholders amounted to USD 3.8 million compared with a net loss of USD 4.7 million in the first half of 2006.

Cash flow

Cash generated in Q2 from SHL's operating activities amounted to USD 0.9 million compared to USD 0.6 million in Q2 of 2006 bringing cash generated from operating activities in the first half of 2007 to USD 0.3 million compared to USD 0.2 million in H1 of 2006.

After balance sheet date, SHL arranged a credit facility in the US with one of the US's leading banks in the amount of USD 12.5 million.

Expected transaction in US

SHL is in the final stages of negotiations regarding a significant and major transaction with regard to its US operations and expects to make an announcement regarding this in the coming days.

New state of the art wireless platform for arrhythmia monitoring

SHL has just received FDA clearance of its new proprietary cardiac looping recorder and transmitter, first in a new family of wireless cellular based devices developed by SHL for diagnostic arrhythmia services and the first wireless cellular looping monitor available in the world. This new device which will soon be available on the US market increases the ease of use for patients carrying out diagnostic arrhythmia testing thus improving patient compliance and resulting in higher diagnostic yields of information for the clinician.

Yours sincerely,

A handwritten signature in black ink that reads 'Y. Alroy'.

Yoram Alroy,
Chairman and President

Contents

3		Review of Unaudited Interim Condensed Consolidated Financial Statements
4		Consolidated Balance Sheets
6		Consolidated Statements of Operations
7		Consolidated Statements of Changes in Equity
8		Consolidated Statements of Cash Flows
2		11 Notes to Interim Consolidated Financial Statements

The Shareholders and Board of Directors SHL Telemedicine Ltd.

Re: Review of unaudited interim consolidated financial statements
for the six months and three months ended June 30, 2007

Introduction

We have reviewed the accompanying interim condensed consolidated financial statements of SHL Telemedicine Ltd. ("the Company") and its subsidiaries as of June 30, 2007, comprising of the interim consolidated balance sheet as of June 30, 2007 and the related interim consolidated statements of operations, changes in equity and cash flows for the six-month period then ended and explanatory notes. Management is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with International Financial Reporting Standard IAS 34, "Interim Financial Reporting" ("IAS 34"). Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making

inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34.

Tel-Aviv, Israel
September 30, 2007

Kost Forer Gabbay and Kasierer
KOST FORER GABBAY & KASIERER
A Member of Ernst & Young Global

Consolidated Balance Sheets U.S. dollars in thousands

	June 30,		December 31,
	2007	2006*)	2006
	Unaudited		Audited
ASSETS			
CURRENT ASSETS:			
Cash and cash equivalents	4,730	6,401	9,678
Short-term investments	1,533	3,066	2,804
Trade receivables	18,451	20,426	18,810
Prepaid expenses	2,821	3,306 **)	3,015 **)
Income tax receivable	364	307	272
Other accounts receivable	330	700	386
Inventory	604	642	604
	28,833	34,848	35,569
Assets of disposal group classified as held-for-sale	230	764	1,106
	29,063	35,612	36,675
LONG-TERM ASSETS:			
Trade receivables	3,041	3,169	3,166
Prepaid expenses	5,738	6,369 **)	6,196 **)
Investment in associate	44	14	46
Long-term deposits	4,349	4,341	4,346
Deferred taxes	6,652	6,838	7,235
	19,824	20,731	20,989
FIXED ASSETS:			
Cost	55,183	55,016	53,795
Less - accumulated depreciation	33,081	29,519	30,134
	22,102	25,497	23,661
INTANGIBLE ASSETS, NET	47,230	48,709	46,994
Total assets	118,219	130,549	128,319

*) Retrospectively restated - see Note 2b.

**) Reclassified.

The accompanying notes are an integral part of the consolidated financial statements.

Consolidated Balance Sheets U.S. dollars in thousands


	June 30,		December 31,
	2007	2006*)	2006
	Unaudited		Audited
LIABILITIES AND EQUITY			
CURRENT LIABILITIES:			
Credit from banks and current maturities of long-term loans	44,006	28,710	29,519
Trade payables	8,704	8,665	7,988
Income tax payable	431	959	535
Other accounts payable	8,641	10,209	9,467
	61,782	48,543	47,509
Liabilities directly associated with the assets classified as held-for-sale (Note 3)	-	205	-
	61,782	48,748	47,509
LONG-TERM LIABILITIES:			
Loans from banks, lease obligations and others	24,758	40,876	44,421
Provisions	2,371	1,829	2,459
Accrued severance pay	800	895	752
Deferred revenues	2,091	3,697	2,828
Deferred taxes	551	509	544
	30,571	47,806	51,004
Total liabilities	92,353	96,554	98,513
EQUITY:			
Equity attributable to equity holders of the parent:			
Issued capital	31	31	31
Additional paid-in capital	92,147	91,893	92,006
Treasury shares at cost	(269)	(269)	(269)
Foreign currency translation reserve	(7,769)	(7,406)	(7,773)
Accumulated deficit	(58,649)	(51,087)	(54,904)
	25,491	33,162	29,091
Minority interest	375	833	715
Total equity	25,866	33,995	29,806
Total liabilities and equity	118,219	130,549	128,319

*) Retrospectively restated - see Note 2b.

The accompanying notes are an integral part of the consolidated financial statements.

September 30, 2007
Date of approval of the
financial statements


Erez Alroy
Co-CEO


Yoram Alroy
Chairman of the Board of
Directors and President

Consolidated Statements of Operations U.S. dollars in thousands (except per share amounts)

	Three months ended		Six months ended		Year ended
	June 30,		June 30,		December 31,
	2007	2006*)	2007	2006*)	2006
	Unaudited		Unaudited		Audited
Continuing operations:					
Revenues	20,287	20,962	40,253	41,506	83,218
Cost of revenues	10,628	10,819	21,010	21,467	42,663
Gross profit	9,659	10,143	19,243	20,039	40,555
Research and development costs, net	296	213	498	403	911
Selling and marketing expenses	3,355	2,753	6,446	5,500	11,422
General and administrative expenses	5,857	5,893	11,716	11,502	23,251
Operating income	151	1,284	583	2,634	4,971
Financial income	566	963	1,471	1,694	3,126
Financial expenses	(2,419)	(1,945)	(4,117)	(3,990)	(6,970)
Other income (expenses), net (Note 5)	17	2	4,770	(66)	(602)
Income (loss) before taxes on income	(1,685)	304	2,707	272	525
Taxes on income	669	2,355	1,121	2,170	429
Income (loss) from continuing operations	(2,354)	(2,051)	1,586	(1,898)	96
Discontinued operations:					
Loss associated with discontinued operations (Note 3)	(382)	(296)	(983)	(1,957)	(7,190)
Net income (loss)	(2,736)	(2,347)	603	(3,855)	(7,094)
Attributable to:					
Equity holders of the parent	(2,741)	(2,805)	(3,745)	(4,647)	(8,464)
Minority interest	5	458	4,348	792	1,370
	(2,736)	(2,347)	603	(3,855)	(7,094)
Basic and diluted loss per share attributable to equity holders of the parent:					
From continuing operations	(0.22)	(0.24)	(0.26)	(0.25)	(0.12)
From discontinued operations	(0.03)	(0.03)	(0.09)	(0.19)	(0.68)
Total loss per share	(0.25)	(0.27)	(0.35)	(0.44)	(0.80)

*) Retrospectively restated - see Note 2b.

The accompanying notes are an integral part of the consolidated financial statements.

Consolidated Statements of Changes in Equity US dollars in thousands

	Attributable to equity holders of the parent					Total	Minority interest	Total equity	Total recognized income (expenses)	
	Issued capital	Additional paid-in capital	Treasury shares	Foreign currency translation reserve	Accumulated deficit				Parent	Minority
Balance at January 1, 2006 (audited)	31	91,762	(269)	(7,168)	(46,440)	37,916	1,152	39,068		
Share-based payments	-	244	-	-	-	244	-	244		
Currency translation differences	-	-	-	(605)	-	(605)	-	(605)	(605)	
Distribution to minority interest	-	-	-	-	-	-	(1,867)	(1,867)		
Change in equity of minority interest	-	-	-	-	-	-	60	60		
Net income (loss)	-	-	-	-	(8,464)	(8,464)	1,370	(7,094)	(8,464)	1,370
Balance at December 31, 2006 (audited)	31	92,006	(269)	(7,773)	(54,904)	29,091	715	29,806	(9,069)	1,370
Share-based payments	-	141	-	-	-	141	-	141	-	-
Currency translation differences	-	-	-	4	-	4	-	4	4	
Distribution to minority interest	-	-	-	-	-	-	(4,688)	(4,688)	-	
Net income (loss)	-	-	-	-	(3,745)	(3,745)	4,348	603	(3,745)	4,348
Balance at June 30, 2007 (unaudited)	31	92,147	(269)	(7,769)	(58,649)	25,491	375	25,866	(3,741)	4,348
Balance at January 1, 2006 (audited)	31	91,762	(269)	(7,168)	(46,440)	37,916	1,152	39,068		
Share based payments	-	131	-	-	-	131	-	131	-	-
Currency translation differences	-	-	-	(238)	-	(238)	-	(238)	(238)	-
Distribution to minority interest	-	-	-	-	-	-	(1,184)	(1,184)	-	-
Change in equity of minority interest	-	-	-	-	-	-	73	73	-	-
Net income (loss)	-	-	-	-	(4,647)	(4,647)	792	(3,855)	(4,647)	792
Balance at June 30, 2006 (unaudited)*	31	91,893	(269)	(7,406)	(51,087)	33,162	833	33,995	(4,885)	792

*) Retrospectively restated - see Note 2b.

The accompanying notes are an integral part of the consolidated financial statements.

Consolidated Statements of Cash Flows US dollars in thousands

	Three months ended		Six months ended		Year ended
	June 30,		June 30,		December 31,
	2007	2006*)	2007	2006*)	2006
	Unaudited		Unaudited		Audited
Cash flows from operating activities:					
Net income (loss)	(2,736)	(2,347)	603	(3,855)	(7,094)
Adjustments required to reconcile net income					
(loss) to net cash provided by operating activities (a)	3,588	2,933	(320)	4,013	8,894
Net cash provided by operating activities	852	586	283	158	1,800
Cash flows from investing activities:					
Purchase of fixed assets	(611)	(1,007)	(1,687)	(2,858)	(5,015)
Cash received upon sale of subsidiary (b)	-	-	5,649	-	2,150
Investment in intangible assets	(277)	(397)	(787)	(1,021)	(1,558)
Proceeds from sale of fixed assets	33	19	181	19	37
Marketable securities, net	1,287	3,203	1,287	(1,526)	(1,133)
Net cash provided by (used in) investing activities	432	1,818	4,643	(5,386)	(5,519)
Cash flows from financing activities:					
Proceeds from long-term loans from banks and others	780	339	1,547	4,781	18,355
Repayment of long-term loans from banks and others	(8,556)	(5,260)	(11,038)	(11,264)	(23,515)
Short-term bank credit, net	4,290	(482)	4,245	(74)	548
Distributions to minority interest	(125)	(589)	(4,688)	(1,184)	(1,867)
Capital contribution from minority interests	-	1	-	73	60
Net cash used in financing activities	(3,611)	(5,991)	(9,934)	(7,668)	(6,419)
Effect of exchange rate changes on cash and cash equivalents	(40)	484	60	234	753
Decrease in cash and cash equivalents	(2,367)	(3,103)	(4,948)	(12,662)	(9,385)
Cash and cash equivalents at the beginning of the period	7,097	9,504	9,678	19,063	19,063
Cash and cash equivalents at the end of the period	4,730	6,401	4,730	6,401	9,678

*) Retrospectively restated - see Note 2b.

The accompanying notes are an integral part of the consolidated financial statements.

Consolidated Statements of Cash Flows US dollars in thousands

	Three months ended		Six months ended		Year ended
	June 30,		June 30,		December 31,
	2007	2006*)	2007	2006*)	2006
	Unaudited		Unaudited		Audited
(a) Adjustments required to reconcile net income (loss)					
to net cash provided by operating activities:					
Income and expenses not involving operating cash flows:					
Loss (gain) on sale of subsidiaries	-	-	(4,773)	-	166
Depreciation and amortization	1,852	1,767	3,471	3,601	8,648
Deferred taxes, net	208	460	568	206	95
Loss (gain) on disposal of fixed assets	(30)	16	32	17	270
Accrued severance pay	40	(157)	54	(169)	(353)
Exchange rate and linkage differences on principal of long-term liabilities, net	431	(853)	117	(496)	(1,121)
Loss (gain) on marketable securities	65	176	(3)	131	75
Exchange rate differences on short and long-term deposits, net	(99)	181	(28)	123	331
Share-based payments	71	74	141	131	244
Others	26	6	28	17	(52)
	2,564	1,670	(393)	3,561	8,303
Changes in operating assets and liabilities:					
Decrease (increase) in short and long-term trade receivables, net	1,324	1,788	454	(328)	2,180
Decrease in prepaid expenses	173	40	618	350	1,282
Decrease (increase) in other accounts receivable	(45)	(111)	(37)	(208)	173
Decrease (increase) in inventory	(4)	32	(4)	23	90
Increase (decrease) in trade payables	363	(1,353)	736	315	(518)
Decrease in deferred revenues	(403)	(287)	(953)	(280)	(1,340)
Increase (decrease) in short and long-term other accounts payable and income tax payable	(384)	1,154	(941)	580	(1,276)
	1,024	1,263	73	452	591
	3,588	2,933	(320)	4,013	8,894

*) Retrospectively restated - see Note 2b.

The accompanying notes are an integral part of the consolidated financial statements.

Consolidated Statements of Cash Flows US dollars in thousands

	Three months ended		Six months ended		Year ended
	June 30,		June 30,		December 31,
	2007	2006	2007	2006	2006
	Unaudited		Unaudited		Audited
(b) Cash received upon sale of subsidiary (Note 5):					
Working capital (excluding cash and cash equivalents)	-	-	-	-	882
Fixed assets, net	-	-	38	-	52
Intangible assets	-	-	838	-	1,382
Gain (loss) on sale of subsidiary	-	-	4,773	-	(166)
	-	-	5,649	-	2,150
(c) Significant non-cash transaction:					
Purchase of fixed assets	-	-	-	-	370
(d) Supplemental disclosure of cash flows activities:					
Interest received	34	250	226	614	873
Interest paid	1,208	1,335	2,303	2,449	4,827
Income taxes paid	170	246	320	362	785

The accompanying notes are an integral part of the consolidated financial statements.

NOTE 1 | GENERAL

a. These financial statements have been prepared as of June 30, 2007, and for the six months and three months then ended. These financial statements are to be read in conjunction with the audited annual financial statements and accompanying notes of SHL Telemedicine Ltd. ("the Company") as of December 31, 2006 ("the annual financial statements").

b. Following are data regarding the Israeli CPI and the exchange rate of the U.S. dollar and Euro:

As of	Israeli CPI Points *)	Exchange rate	Exchange rate
		of € 1 NIS	of U.S. \$ 1 NIS
June 30, 2007	110.97	5.7132	4.249
June 30, 2006	111.71	5.6435	4.44
December 31, 2006	109.9	5.5643	4.225
Change during the period	%	%	%
June 2007 (six months)	0.07	0.03	0.006
June 2007 (three months)	0.33	0.03	0.02
June 2006 (six months)	1.5	3.6	(3.5)
June 2006 (three months)	1	(0.3)	(4.8)
December 2006 (12 months)	(0.1)	2.2	(8.2)

*) The index on an average basis of 2000 = 100.

NOTE 2 | SIGNIFICANT ACCOUNTING POLICIES

a. The interim consolidated financial statements are prepared in accordance with the principles set forth in IAS 34. The significant accounting policies and methods of measurement applied in the annual consolidated financial statements of the Company as of December 31, 2006, are applied consistently in these financial statements.

b. Retrospective restatements:

As described in the annual financial statements, the Company has restated the financial statements as of June 30, 2006, and for the six months and three months then ended to reflect the effects of the following changes:

1. In 2006, the Company discovered an error whereby some subscribers who received discounts in prior years and are still receiving service were accounted for as if they had cancelled the service.
2. In 2006, the Israeli Accounting Standards Board determined in accordance with IAS 29 that the Israeli economy ceased to be hyperinflationary as of December 31, 2003. Accordingly, the financial statements of the parent company and its subsidiaries in Israel should have been adjusted for the effects of inflation until that date. Those financial statements had previously been presented until that date based on historical cost without adjustment for the effects of inflation.
3. In 2006, the calculation of the accrued severance pay was amended to reflect the fair value of the plan assets in respect of the defined benefit plan for severance pay.

The effects of the changes on the financial statements are as follows:

Balance sheet:	June 30, 2006 (Unaudited)		
	As previously reported	The change	As presented in these financial statements
Prepaid expenses *)	9,129	549	9,678
Fixed assets, net	25,307	190	25,497
Goodwill	42,282	648	42,930
Deferred tax assets	5,554	1,284	6,838
Accrued severance pay	66	829	895
Deferred revenues *)	866	3,646	4,512
Foreign currency translation reserve	(7,381)	(10)	(7,391)
Accumulated deficit	(49,317)	(1,794)	(51,111)

*) Including current portion.

Statements of operations:	Three months ended			Six months ended		
	June 30, 2006 (unaudited)			June 30, 2006 (unaudited)		
	As previously reported	The change	As presented in these financial statements *)	As previously reported	The change	As presented in these financial statements *)
Revenues	21,050	124	21,174	44,033	46	44,079
Cost of revenues	10,935	23	10,958	23,344	39	23,383
Selling and marketing expenses	2,794	(45)	2,749	5,726	(97)	5,629
Financial expenses	1,206	(6)	1,200	2,743	(6)	2,737
Taxes on income	494	169	663	376	120	496
Loss	(2,354)	(17)	(2,371)	(3,869)	(10)	(3,879)
Attributable to equity holders of the parent	(2,812)	(17)	(2,829)	(4,661)	(10)	(4,671)
Basic and diluted loss per share attributable to equity holders of the parent	(0.27)	-	(0.27)	(0.44)	-	(0.44)
Statements of changes in equity -						
Accumulated deficit - January 1, 2006	(44,656)	(1,784)	(46,440)	(44,656)	(1,784)	(46,440)

*) Before reclassification of discontinued operations that occurred in 2006.

NOTE 3 | DISCONTINUED OPERATIONS

During 2006, a wholly-owned subsidiary of the Company, SHL Telemedicine North American (“NA”) sold the operations of three of its imaging centers and closed two other imaging centers. Upon further review of the remaining imaging centers, NA decided in 2006 to sell the operations of the centers during 2007. As a result of this decision, all imaging centers have been reported as discontinued operations.

Subsequent to the balance sheet date, NA closed on the sale of the five remaining imaging centers for \$275. In connection with the sale, no material gain or loss is expected to result.

The results of the discontinued operations are presented below:

	Three months ended		Six months ended		Year ended
	June 30,		June 30,		December 31,
	2007	2006	2007	2006	2006
Revenues	1,321	2,301	2,635	4,662	7,505
Cost of revenues	(1,005)	(1,568)	(2,037)	(3,345)	(5,520)
Selling, general and administrative	(1,083)	(2,193)	(1,958)	(4,155)	(6,733)
Other expenses	(81)	(550)	(134)	(816)	(2,374)
Taxes on income (tax benefit)	466	1,714	511	1,697	(68)
Loss	(382)	(296)	(983)	(1,957)	(7,190)

The net cash flows of discontinued operations are as follows:

	Three months ended		Six months ended		Year ended
	June 30,		June 30,		December 31,
	2007	2006	2007	2006	2006
Operating cash flows	(403)	(1,013)	(870)	(1,728)	114
Investing cash flows	66	474	64	264	42
Financing cash flows	293	574	715	1,480	(201)
Net cash outflow	(44)	35	(91)	16	(45)

NOTE 4 | SEGMENT INFORMATION

a. The Company and its subsidiaries operate in two business segments:

Telemedicine services - providing telemedicine services and devices to subscribers utilizing telephonic and Internet communication technology. SHL's telemedicine solution offers centralized remote diagnostic and monitoring services to end-users, making use of computer systems, hi-tech devices, and specially designed medical data protocols. SHL's platform offers solutions to subscribing patients, health insurance companies, hospitals, clinics, physicians and other health care providers.

Medical services - operating a network of cardiac facilities that provide diagnostic, therapeutic and patient management services primarily associated with cardiovascular diseases.

b. The following tables present revenue and profit information regarding business segments:

	Three months ended June 30, (unaudited)					
	Telemedicine services		Medical services		Consolidated	
	2007	2006	2007	2006	2007	2006
Segment revenues	15,872	15,687	4,415	5,275	20,287	20,962
Segment results	98	801	1,096	1,346	1,194	2,147
Unallocated expenses					(1,043)	(863)
Operating income					151	1,284

	Six months ended June 30, (unaudited)					
	Telemedicine services		Medical services		Consolidated	
	2007	2006	2007	2006	2007	2006
Segment revenues	31,514	31,105	8,739	10,401	40,253	41,506
Segment results	1,107	1,926	1,526	2,475	2,633	4,401
Unallocated expenses					(2,050)	(1,767)
Operating income					583	2,634

	Year ended December 31, 2006 (audited)		
	Telemedicine services	Medical services	Consolidated
Segment revenues	62,848	20,370	83,218
Segment results	4,001	4,666	8,667
Unallocated expenses			(3,696)
Operating income			4,971

NOTE 5 | SALE OF SUBSIDIARY

On February 9, 2007, NA sold one of its catherization labs, in which it exercised control and held a 20% interest. Total proceeds were \$ 5,649 and a gain (before income taxes) of \$ 4,773 was recognized. NA's portion of the gain is \$ 292 (before income taxes and after minority interest).

Information for investors

SHL TeleMedicine: profile

SHL TeleMedicine Ltd. is a leading provider and developer of advanced personal telemedicine solutions to individuals and to the healthcare community. As a leading provider of remote health services in cardiology and in other medical areas, SHL maintains business operations in the US, Europe and Israel.

Capital structure

The issued share capital is divided into 10,679,051 registered shares with a par value of NIS 0.01 each

Significant shareholders'

Shareholders' with more than 5% of all shares may be registered. There are no restrictions on voting rights.

Royal Philips Electronics	18.65%
Alroy Group*	18.60%
Tower Holdings B.V.	14.24%
G.Z. Assets and Management Ltd.	8.68%
Public	39.83%

The above table of Significant Shareholders reflects actual holdings in accordance with the SAG Register as of June 30, 2007, after deducting from the total number of shares outstanding 61,159 Ordinary Shares held by SHL, and does not reflect holdings on a fully diluted basis.

Statistics on SHL Telemedicine as at June 30, 2007

Registered shares with a par value of NIS 0.01 each

Securities number	1128957
Number of shares	10,679,051
Market price high/low (CHF)	8.60/4.82
Market capitalization high/low (CHF million)	91.8/51.5
Market capitalization 30/6/2007 (CHF million)	89.2
Share capital – nominal value (NIS)	106,773
Majority interests	60.17%

Share price development



Listing

All SHL shares are listed on SWX Swiss Exchange
 Ticker symbol: SHL TN
 Currency: CHF
 Listing date: November 15, 2000

Investor relations

SHL Telemedicine Ltd.
 Erez Alroy, Co-CEO
 Haim Brosh, Executive Vice President Finance
 90 Igal Alon St., Tel Aviv 67891, Israel
 Tel. ++972 3 561 2212
 Fax: ++972 3 624 2414
 Email: ereza@shl-telemedicine.com
 Email: haim@shl-telemedicine.com

Next Publications

Q3 Results: November 22, 2007